These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16296649)

  • 1. [Cyclooxygenase-2 inhibitors and the ethics of research].
    Gherardi CR
    Medicina (B Aires); 2005; 65(5):476. PubMed ID: 16296649
    [No Abstract]   [Full Text] [Related]  

  • 2. COX-2 inhibitors--a lesson in unexpected problems.
    Drazen JM
    N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
    [No Abstract]   [Full Text] [Related]  

  • 3. COX-2 inhibitors--lessons in drug safety.
    Psaty BM; Furberg CD
    N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cyclooxygenase inhibitors: a never ending story?].
    Macrì R; Manfredi C
    G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
    [No Abstract]   [Full Text] [Related]  

  • 5. Raising the safety bar--the FDA's coxib meeting.
    Okie S
    N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract]   [Full Text] [Related]  

  • 6. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 7. Painful lessons.
    Nat Struct Mol Biol; 2005 Mar; 12(3):205. PubMed ID: 15744317
    [No Abstract]   [Full Text] [Related]  

  • 8. The Vioxx debacle revisited.
    Abeles M; Abeles AM
    Am J Med; 2005 Sep; 118(9):1057-8. PubMed ID: 16164907
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
    Bolten WW; Reiter S;
    Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous vasculitis induced by cyclo-oxygenase-2 selective inhibitors.
    Drago F; Brusati C; Desirello G; Cacciapuoti M; Rebora A
    J Am Acad Dermatol; 2004 Dec; 51(6):1029-30. PubMed ID: 15583611
    [No Abstract]   [Full Text] [Related]  

  • 11. The pain game.
    Wadman M
    Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 13. Institutional review boards must conduct safety review.
    Maloney DM
    Hum Res Rep; 2005 Feb; 20(2):3. PubMed ID: 15839005
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
    Jugdutt BI
    Circulation; 2007 Jan; 115(3):288-91. PubMed ID: 17242292
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER
    Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
    [No Abstract]   [Full Text] [Related]  

  • 16. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
    Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
    [No Abstract]   [Full Text] [Related]  

  • 17. The COX-2 inhibitors--an update.
    Furberg CD
    Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
    [No Abstract]   [Full Text] [Related]  

  • 18. Does the dose make the poison?
    Harris RE
    Science; 2005 Apr; 308(5719):203. PubMed ID: 15821073
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular risk associated with celecoxib.
    Brophy JM
    N Engl J Med; 2005 Jun; 352(25):2648-50; author reply 2648-50. PubMed ID: 15972876
    [No Abstract]   [Full Text] [Related]  

  • 20. Cox-2 inhibitors: still no decisive action.
    Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.